Patents matching “formulation”

US 10471148

Progesterone formulations having a desirable PK profile

Compass Therapeutics LLC · Granted Nov 12, 2019 · Expires Nov 7, 2039

US 10472425

Stabilized formulations containing anti-PCSK9 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Nov 12, 2019 · Expires Nov 7, 2039

US 10464992

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Nov 5, 2019 · Expires Oct 31, 2039

US 10456346

Cosmetic formulations for topical applications containing erythropoietin-derived molecules

ASC REGENITY LIMITED · Granted Oct 29, 2019 · Expires Oct 24, 2039

US 10449185

Formulations of pimavanserin

ACADIA Pharmaceuticals Inc. · Granted Oct 22, 2019 · Expires Oct 17, 2039

US 10435473

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Oct 8, 2019 · Expires Oct 3, 2039

US 10434167

Non-toxic adjuvant formulation comprising a monophosphoryl lipid A (MPLA)-containing liposome composition and a saponin

The Government of the United States, as represented by the Secretary of the Army · Granted Oct 8, 2019 · Expires Oct 3, 2039

CA 3094934

FORMULATIONS AQUEUSES STABLES D'ANTICORPS ANTI-TAU

ABBVIE DEUTSCHLAND [DE] · Granted Sep 26, 2019 · Expires Sep 21, 2039

US 10414656

Discrete carbon nanotubes with targeted oxidation levels and formulations thereof

MOLECULAR REBAR DESIGN, LLC · Granted Sep 17, 2019 · Expires Sep 12, 2039

US 10406160

Sustained release small molecule drug formulation

Indivior UK Limited · Granted Sep 10, 2019 · Expires Sep 5, 2039

US 10406194

Powder formulation, method for preparing the same and use thereof

INFINITUS (CHINA) COMPANY LTD. · Granted Sep 10, 2019 · Expires Sep 5, 2039

US 10400025

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Sep 3, 2019 · Expires Aug 29, 2039

US 10398662

GHB formulation and method for its manufacture

JAZZ PHARMA IRELAND LIMITED · Granted Sep 3, 2019 · Expires Aug 29, 2039

US 10391170

Stable anti-OSMR antibody formulation

Kiniksa Pharmaceuticals, GmbH · Granted Aug 27, 2019 · Expires Aug 22, 2039

US 10376582

Buffer formulations for enhanced antibody stability

Outlook Therapeutics, Inc. · Granted Aug 13, 2019 · Expires Aug 8, 2039

US 10376588

Etanercept formulations stabilized with combinations of sugars and polyols

Coherus BioSciences, Inc. · Granted Aug 13, 2019 · Expires Aug 8, 2039

US 10376590

Sustained delivery formulations of risperidone compound

Indivior UK Limited · Granted Aug 13, 2019 · Expires Aug 8, 2039

US 10369229

Methods and compositions for liposomal formulation of antigens and uses thereof

The Regents of the University of California · Granted Aug 6, 2019 · Expires Aug 1, 2039

US 10357465

Eutectic formulations of cyclobenzaprine hydrochloride

TONIX PHARMA LIMITED · Granted Jul 23, 2019 · Expires Jul 18, 2039

US 10350183

Intravenous baclofen formulations and treatment methods

Regents of the University of Minnesota · Granted Jul 16, 2019 · Expires Jul 11, 2039

US 10350296

Chewable gelatin formulations

Aspire Pharmaceuticals · Granted Jul 16, 2019 · Expires Jul 11, 2039

US 10342876

Process for reducing subvisible particles in a pharmaceutical formulation

REGENERON PHARMACEUTICALS, INC. · Granted Jul 9, 2019 · Expires Jul 4, 2039

US 10335391

Stabilized oxymetazoline formulations and their uses

Aclaris Therapeutics, Inc. · Granted Jul 2, 2019 · Expires Jun 27, 2039

US 10328087

Formulations for solubilizing hormones

Compass Therapeutics LLC · Granted Jun 25, 2019 · Expires Jun 20, 2039